Clinical trials using monoclonal antibodies such as temelimab, which specifically targets the HERV-W envelope protein, have shown significant promise in patients with MS, demonstrating reductions in neuroinflammatory markers, protection of myelin integrity, and clinical stabilization [80,81]. This evidence concerns the gene ERVW-1 and myeloid sarcoma.